Research advances in the impact of tacrolimus on glucose metabolism after kidney transplantation
10.12464/j.issn.1674-7445.2025109
- VernacularTitle:肾移植术后他克莫司影响血糖代谢的研究进展
- Author:
Haoran SHI
1
;
Shanda LI
;
Kun WANG
;
Yuxiang CHEN
;
Zhuocheng LI
;
Yu ZHANG
;
Xuyuan ZHU
;
Liang GAO
;
Hongtao JIANG
Author Information
1. 570311 海口,海南医科大学第二附属医院肾移植科
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Tacrolimus;
Blood glucose metabolism;
Post transplantation diabetes mellitus;
End-stage renal disease;
Peroxisome proliferator-activated receptor;
Mammalian target of rapamycin;
Calcineurin inhibitor
- From:
Organ Transplantation
2025;16(5):778-784
- CountryChina
- Language:Chinese
-
Abstract:
Kidney transplantation is an effective treatment for end-stage renal disease.However,post transplantation diabetes mellitus(PTDM)is a common complication after kidney transplantation,affecting 10%to 40%of recipients and increasing the risk of cardiovascular disease,infections,sepsis and other conditions.The pathogenesis of PTDM is complex,including pancreatic β-cell dysfunction and insulin resistance.Tacrolimus,a commonly used immunosuppressive drug,is an independent risk factor for PTDM.Its mechanisms include damaging pancreatic β-cells,mediating impaired mitochondrial autophagy,etc.In addition,tacrolimus also raises blood glucose levels through various pathways,such as affecting gut microbiota metabolism and activating bile acid signaling pathways.In recent years,some new anti-diabetic drugs have shown certain application prospects in kidney transplant recipients,but the evidence-based medical evidence for their combined use still needs further exploration.In the future,it is necessary to conduct in-depth research on the multiple sites of action of tacrolimus to reduce the occurrence of PTDM and improve the prognosis of kidney transplant recipients.
